WILMINGTON…PPD Inc. (Nasdaq:PPDI) has named Steadman Harrison, Ph.D., senior research director and executive director of research and development at Piedmont Research Center.
The Center is the company’s preclinical cancer research division.
Harrison will direct the laboratories and lead a specialized team of scientists in conducting evaluations of anticancer therapies.
Prior to joining Piedmont Research Center, Harrison served as executive
director of experimental medicine and executive director of business
development at EMD Pharmaceuticals, Inc. (Merck KGaA). In previous roles, he
was vice president of preclinical development at Sphinx Pharmaceuticals
Corp. and director of cancer research and advisor of research
acquisitions at Eli Lilly and Company.
He began his career with Southern Research Institute where he rose to the
position of head of the pharmacology section and later served as director of
chemotherapy research. He has served on the faculties of the University of
Kentucky Graduate Center for Toxicology and the University of Alabama at
Birmingham and is currently an adjunct faculty member of the Comprehensive
Cancer Center at Duke University Medical Center.
